CHARACTERISTICS
ACTIVE HALF-LIFE 14 DAYS
CLASSIFICATION ANABOLIC STEROID
DOSAGE MEN 200-600 MG/WEEK
ACNE RARELY
WATER RETENTION YES
HBR NO
HEPATOTOXICITY YES
AROMATIZATION NO
ACTIVE SUBSTANCE TRENBOLONE HEXAHYDROBENZYLCARBONATE
FORM 10 ML X 75 MG/ML
MANUFACTURER HILMA BIOCARE
CHARACTERISTICS
ACTIVE HALF-LIFE 14 DAYS
CLASSIFICATION ANABOLIC STEROID
DOSAGE MEN 200-600 MG/WEEK
ACNE RARELY
WATER RETENTION YES
HBR NO
HEPATOTOXICITY YES
AROMATIZATION NO
ACTIVE SUBSTANCE TRENBOLONE HEXAHYDROBENZYLCARBONATE
FORM 10 ML X 100 MG/ML
MANUFACTURER DRAGON PHARMA
CHARACTERISTICS
ACTIVE HALF-LIFE 14 DAYS
CLASSIFICATION ANABOLIC STEROID
DOSAGE MEN 200-600 MG/WEEK
ACNE RARELY
WATER RETENTION YES
HBR NO
HEPATOTOXICITY YES
AROMATIZATION NO
ACTIVE SUBSTANCE TRENBOLONE HEXAHYDROBENZYLCARBONATE
FORM 10 ML X 100 MG/ML
MANUFACTURER SIS LABS
CHARACTERISTICS
ACTIVE HALF-LIFE 14 DAYS
CLASSIFICATION ANABOLIC STEROID
DOSAGE MEN 200-600 MG/WEEK
ACNE RARELY
WATER RETENTION YES
HBR NO
HEPATOTOXICITY YES
AROMATIZATION NO
ACTIVE SUBSTANCE TRENBOLONE HEXAHYDROBENZYLCARBONATE
FORM 5 X 1.5 ML X 76.5 MG
MANUFACTURER ALPHA PHARMA
CHARACTERISTICS
ACTIVE HALF-LIFE: 4-5 HOURS
CLASSIFICATION: PDE5 INHIBITOR
DOSAGE: MEN 100 MG/DAY
ACNE: NO
WATER RETENTION: NO
HBR: POSSIBLE
HEPATOTOXICITY: NO
AROMATIZATION: NO
ACTIVE SUBSTANCE: SILDENAFIL
FORM: 4 PILLS X 100 MG
MANUFACTURER: Zydus Cadila Healthcare Ltd
DISEASE INDICATIONS: Breast Cancer
MANUFACTURER: Roche Registration Limited
USAGE: Intravenous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Perjeta, also known by its generic name Pertuzumab, is a monoclonal antibody drug developed by Genentech, a member of the Roche Group. It was approved by the United States Food and Drug Administration (FDA) in 2012, marking a significant milestone in the treatment of HER2-positive breast cancer, a particularly aggressive and fast-growing form of the disease. Perjeta is often used in combination with other medications, most notably Herceptin (Trastuzumab), and chemotherapy agents like docetaxel.
